Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

75%(3 trials)

Phase Distribution

Ph phase_1

60%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

3(60.0%)

Phase 2Efficacy & side effects

2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(1)

Detailed Status

Completed4

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (60.0%)

Phase 22 (40.0%)

Trials by Status

completed480%

withdrawn120%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_1

Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

NCT01394939

completedphase_1

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

NCT00429312

completedphase_2

A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma

NCT01171651

completedphase_1

A Trial of JX-594 in Refractory Colorectal Carcinoma

NCT01469611

withdrawnphase_2

Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin

NCT02017678

Clinical Trials (5)

Showing 5 of 5 trials

NCT01394939Phase 1

Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

Completed

NCT00429312Phase 1

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

Completed

NCT01171651Phase 2

A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma

Completed

NCT01469611Phase 1

A Trial of JX-594 in Refractory Colorectal Carcinoma

Completed

NCT02017678Phase 2

Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin

Withdrawn

All 5 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 5